



Published in final edited form as:

Ophthalmology. 2014 February ; 121(2): 508–516. doi:10.1016/j.ophtha.2013.09.012.

Association of CAV1/CAV2 genomic variants with primary open angle glaucoma overall and by gender and pattern of visual field loss

Stephanie J. Loomis¹, Jae H. Kang², Robert N. Weinreb³, Brian L. Yaspan⁴, Jessica N. Cooke Bailey⁵, Douglas Gaasterland⁶, Terry Gaasterland⁷, Richard K. Lee⁸, Paul R. Lichter⁹, Donald L. Budenz¹⁰, Yutao Liu^{11,12}, Tony Realini¹³, David S. Friedman¹⁴, Catherine A. McCarty¹⁵, Sayoko E. Moroi⁹, Lana Olson⁵, Joel S. Schuman¹⁶, Kuldev Singh¹⁷, Douglas Vollrath¹⁸, Gadi Wollstein¹⁶, Donald J. Zack¹⁴, Murray Brilliant¹⁹, Arthur J. Sit²⁰, William G. Christen², John Finger²¹, Peter Kraft²², Kang Zhang³, R. Rand Allingham¹¹, Margaret A. Pericak-Vance⁸, Julia E. Richards⁹, Michael A. Hauser^{11,12}, Jonathan L. Haines⁵, Louis R. Pasquale^{1,2,*}, and Janey L. Wiggs^{1,*}

¹Department of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear, Boston, MA

²Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

³Department of Ophthalmology and Hamilton, University of California, San Diego, SD, CA

⁴Genentech Inc, San Francisco, CA

⁵Center for Human Genetics Research, Vanderbilt University School of Medicine, Nashville, TN

⁶Eye Doctors of Washington, Chevy Chase, MD

⁷Scripps Genome Center, University of California at San Diego, San Diego, CA

⁸Bascom Palmer Eye Institute and Human Genomics, University of Miami Miller School of Medicine, Miami, FL

⁹Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI

¹⁰Department of Ophthalmology, University of North Carolina, Chapel Hill, NC

¹¹Department of Ophthalmology, Duke University Medical Center, Durham, NC

¹²Department of Medicine, Duke University Medical Center, Durham, NC

¹³Department of Ophthalmology, West Virginia University Eye Institute, Morgantown, WV

¹⁴Wilmer Eye Institute, Johns Hopkins University Hospital, Baltimore, MD

¹⁵Essentia Institute of Rural Health, Duluth, MN

© 2013 American Academy of Ophthalmology, Inc. Published by Elsevier Inc. All rights reserved.

Corresponding author: Janey L. Wiggs, MD, PhD.

*These authors contributed equally to the manuscript.

Meeting presentation: This work has been presented as a poster at the Association for Research in Vision and Ophthalmology 2013 meeting.

Conflict of interest: No conflicting relationship exists for any author.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

¹⁶Department of Ophthalmology, UPMC Eye Center, University of Pittsburgh, Pittsburgh, PA

¹⁷Department of Ophthalmology, Stanford University, Palo Alto, CA

¹⁸Department of Genetics, Stanford University, Palo Alto, CA

¹⁹Center for Human Genetics, Marshfield Clinic Research Foundation, Marshfield, WI

²⁰Department of Ophthalmology, Mayo Clinic, Rochester, MN

²¹Departments of Ophthalmology and Anatomy/Cell Biology, University of Iowa, College of Medicine

²²Departments of Epidemiology and Biostatistics, Harvard School of Public Health, Boston, MA

Abstract

PURPOSE—The *CAVI/CAV2* (caveolin 1 and 2) genomic region has been previously associated with primary open angle glaucoma (POAG), although replication among independent studies has been variable. The aim of this study is to assess the association between *CAVI/CAV2* single nucleotide polymorphisms (SNPs) and POAG in a large case-control dataset and to further explore associations by gender and pattern of visual field (VF) loss.

DESIGN—case-control study

PARTICIPANTS—We analyzed two large POAG datasets, the Glaucoma Genes and Environment (GLAUGEN) study (976 cases, 1140 controls) and the National Eye Institute Glaucoma Human Genetics Collaboration (NEIGHBOR) consortium (2132 cases, 2290 controls).

METHODS—We studied the association between 70 SNPs located within the *CAVI/CAV2* genomic region in GLAUGEN and NEIGHBOR, both genotyped on the Illumina Human 660WQuadv1C BeadChip array and imputed with MACH using the HapMap 3 reference panel. We used logistic regression models of POAG in the overall population and separated by gender, as well as by POAG subtypes defined by type of visual field defect (peripheral or paracentral). Results from GLAUGEN and NEIGHBOR were meta-analyzed and a Bonferroni corrected significance level of 7.7×10^{-4} was used to account for multiple comparisons.

MAIN OUTCOME MEASURES—Overall POAG, overall POAG by gender and POAG subtypes defined by pattern of initial visual field loss.

RESULTS—We found significant associations between ten *CAVI/CAV2* SNPs and POAG (top SNP rs4236601, pooled $p=2.61 \times 10^{-7}$). Of these, nine were significant only in women (top SNP rs4236601, pooled $p=1.59 \times 10^{-5}$). Five of the ten *CAVI/CAV2* SNPs were associated with POAG with paracentral VF loss only (top SNP rs17588172, pooled $p=1.07 \times 10^{-4}$), and none of the ten was associated with POAG with peripheral VF loss only or POAG among men.

CONCLUSIONS—*CAVI/CAV2* SNPs were significantly associated with POAG overall, particularly among women. Furthermore, we found an association between *CAVI/CAV2* SNPs and POAG with paracentral visual field defects. These data support a role for caveolins 1 and/or 2 in POAG and suggest that the caveolins may particularly affect POAG pathogenesis in women and in patients with initial paracentral visual field defects.

Introduction

Primary open-angle glaucoma (POAG) is a leading cause of blindness worldwide, affecting over 35 million people.^{1, 2} POAG is characterized by retinal ganglion cell death and defects in the visual field that ultimately cause functional visual loss.¹ POAG has a genetic component, with contributions from both rare, highly penetrant alleles (*MYOC*, *OPTN*)^{3, 4} and common risk alleles with smaller effects (*CAVI/CAV2*, *TMC01*, *SIX1/SIX6*,

CDKN2BAS, and *8q22*).⁵⁻⁸ The genomic region that includes *CAVI* and *CAV2* was initially identified in a genome-wide association study (GWAS) using cases and controls from Iceland.⁸ Significant associations in this region were also observed in the Glaucoma Genes and Environment (GLAUGEN) study using a sample consisting of 976 cases and 1140 controls.⁹ However, three other smaller studies including 545 cases and 297 controls from Iowa,¹⁰ 220 cases and 405 controls from Saudi Arabia¹¹ and 272 cases and 165 controls from Barbados,¹² have not replicated the overall association between *CAVI/CAV2* single nucleotide polymorphisms (SNPs) and POAG. This is likely due to modest associations that necessitate large sample sizes for detection.

CAVI and *CAV2* code for caveolin 1 and caveolin 2, which are members of the caveolin protein family. These proteins inhibit endothelial nitric oxide synthase (eNOS, coded by the gene *NOS3*, or nitric oxide synthase) activity within the caveolae, which are specialized invaginations of the plasma membrane that are especially prevalent in endothelial plasma membranes.¹³ This interaction alters nitric oxide generation and hence may lead to changes in vascular tone^{14, 15} and trabecular meshwork function,¹⁶ both of which have been implicated in POAG pathogenesis.¹⁷

Estrogen receptors are expressed in retinal ganglion cells,¹⁸ and estrogen is neuroprotective in animal models of POAG^{9, 19}. Higher estrogen levels affect the expression of *NOS3*²⁰ leading to increased nitric oxide production, which may be protective against POAG.^{13, 21} Our group reported gene-environment interactions between *NOS3* single nucleotide polymorphisms (SNPs) and post-menopausal hormone use with high tension POAG²² and between age at menarche and *NOS3* SNPs with overall POAG.²³ As endothelial nitric oxide synthase (*NOS3*) directly interacts with caveolin 1 (*CAVI*),²⁴ there is a strong rationale to assess the impact of gender on the association of *CAVI/CAV2* genomic variations with POAG.

The interaction between caveolin 1 and eNOS in the caveolae of the plasma membranes suggests that the *CAVI/CAV2* genomic region SNPs may be associated with the POAG clinical subgroups that exhibit systemic vascular dysregulation. Several clinical parameters have been observed with higher frequency in POAG cases exhibiting systemic vascular dysregulation including paracentral visual field loss and disc hemorrhages.²⁵ Furthermore, emerging evidence suggests that enzymes that influence vascular physiology, such as soluble guanylyl cyclase (sGC) are associated with initial paracentral loss in POAG patients. Buys et al. demonstrated that sGC knockout mice, which have defective nitric oxide signaling, develop open angle glaucoma and that variants in the genomic region containing genes for the $\alpha 1$ and $\beta 1$ subunits of soluble guanylate cyclase are associated with paracentral visual field loss in women.²⁶ Since the caveolins are an integral part of the nitric oxide signaling pathway, there is interest in whether the *CAVI/CAV2* genomic region SNPs associated with POAG are also associated with the POAG subgroup that is defined by initial paracentral visual loss.

In this study, we investigate the association between SNPs located in the *CAVI/CAV2* genomic region and overall POAG, as well as overall POAG separately by gender and by POAG subgroups defined by pattern of initial visual field loss.

Methods

Study populations

We used two POAG case-control groups in this study: the Glaucoma Genes and Environment (GLAUGEN) study, and the National Eye Institute Glaucoma Human Genetics Collaboration (NEIGHBOR) study. The GLAUGEN study (976 cases, 1140 controls)

consists of two longitudinal cohort studies, the Nurses' Health Study (NHS), and the Health Professionals Follow-Up Study (HPFS) and one clinic based study from the Massachusetts Eye and Ear Infirmary, the Genetic Etiologies of Primary Open-Angle Glaucoma study (GEP). The NEIGHBOR study (2132 cases, 2290 controls) consists of clinic-based case-control studies from twelve sites across the United States. Details of these studies, along with inclusion criteria, have been published previously.^{9, 27} The institutional review boards of the Massachusetts Eye and Ear Infirmary, Harvard School of Public Health, the Brigham and Women's Hospital, University of Pittsburgh, Johns Hopkins University, Duke University, University of West Virginia, University of Miami, University of Michigan, Stanford University, Marshfield Clinic, and the University of California, San Diego approved this study. Informed consent was obtained from all participants.

Case and control definition

Definitions for POAG cases and controls have been previously described.²⁷ Briefly, cases had visual field defects consistent with nerve fiber layer pathology occurring in the setting of a slit lamp biomicroscopic exam that did not reveal any significant findings (aside from possible media opacities) and open angles, regardless of intraocular pressure (IOP). Visual field (VF) loss was either reproduced on a subsequent test, with the same region of the visual field exhibiting VF loss on both visual field reports, and if it was not, there were signs suggestive of glaucomatous cupping as indicated by a cup to disc ratio (CDR) >0.7 . Controls were under ophthalmic surveillance, with an eye exam within the last two years indicating CDR <0.6 and IOP <22 .

Visual Field scoring

For each participant, we obtained the earliest available reliable VF that demonstrated defects consistent with nerve fiber layer pathology. Most VFs were performed with Humphrey Visual Field Analyzers (Carl Zeiss, Dublin, CA) ($>70\%$) although other types of parametric data derived from perimeters such as the Dicon Perimeter (Vision Systems, inc.; Taron Springs FL) or Octopus Perimeter (Haag-Streit; Bern, Switzerland) were used if no Humphrey VFs were available. Reliable VFs were defined based on having fixation loss 33% , false positive rates 20% , and false negative rates 20% . Regardless of VF type, each VF underwent systematic review whereby the pattern deviation plot (PD) was subdivided into paracentral, Bjerrum, nasal step and temporal wedge zones above and below the horizontal meridian (Figure 1). We examined these regions for clusters of three or more contiguous points with retinal sensitivity depression of one half log unit (-5 dB) relative to age-matched controls. Fields with isolated loss in the paracentral zone only without loss in other zones were labeled as paracentral loss cases. If the other zones were involved without loss in the paracentral zone, then the case was categorized as having only peripheral loss. Patients with both paracentral and peripheral VF loss were considered to have advanced functional deficits and were not included in secondary analysis based on type of visual field loss. Two reviewers assessed the VFs masked to genotype status and any differences were adjudicated to arrive at a consensus designation.

Genotyping and Imputation

We used the Illumina Human 660WQuadv1C BeadChip array (Illumina; San Diego, CA) to genotype all samples. Genotyping for GLAUGEN study participants occurred at the Broad Institute (Cambridge, MA), while genotyping for NEIGHBOR consortium participants was performed at the Center for Inherited Disease Research (Baltimore, MD). Details regarding quality control and data cleaning steps have been described previously.⁶ All data have been imputed with MACH (University of Michigan Center for Statistical Genetics, Available at: <http://www.sph.umich.edu/csg/abecasis/MACH>. Accessed Sept 9, 2012.) to the HapMap 3 reference panel.

SNP selection

All SNPs within 50kb upstream of *CAV2*, in and between *CAV2* and *CAVI*, and within 50kb downstream of *CAVI* were selected using the UCSC Genome Browser Table Browser tool (Feb 2009 CRCh37/hg19 assembly, Common SNPs(137) track; UCSC Genome Browser, Available at: www.genome.ucsc.edu. Accessed Sept 9, 2012). Subsequently we used the SNAP proxy search application (CEU population panel, distance limit of 500 bp, using a combination of 1000 Genomes Pilot 1, HapMap 22 and HapMap3 to maximize number of included SNPs; Broad Institute, Available at: <http://www.broadinstitute.org/mpg/snap/ldsearch.php>. Accessed Sept 9, 2012) to obtain a list of SNPs in strong linkage disequilibrium (LD) ($R^2 > 0.8$) with the selected SNPs. Of these, 70 SNPs were in both the GLAUGEN and NEIGHBOR datasets, and were evaluated in these analyses. The genomic locations of the SNPs included in this study are shown in Figure 2.

Statistical analysis

Logistic regression was performed separately in GLAUGEN and NEIGHBOR (lambda inflation factor=1.009, 1.034, respectively)⁶ using ProbABEL (Erasmus University Medical Center, Available at: <http://www.genabel.org/packages/ProbABEL>. Accessed Sept 9, 2012). Subsequently, the results were pooled using the inverse weighted variance method based on regression coefficients and standard errors using the program METAL (University of Michigan Center for Statistical Genetics, Available at: <http://www.sph.umich.edu/csg/abecasis/metal>. Accessed Sept 9, 2012.) with the GENOMICCONTROL option on to correct for any residual population stratification or relatedness. In the GLAUGEN sample, we controlled for age, DNA source (blood or cheek), gender, site, method of extraction, and three principal components that adjust for population stratification. In the NEIGHBOR sample, we controlled for age, gender, site and two principal components. We performed an assessment for heterogeneity prior to combining data from the two studies. The analyses were first run using all participants, and then analyses were performed using men only and women only, as well as cases with only paracentral VF loss (no involvement of the temporal wedge region, Bjerrum areas and nasal step zones in either eye) and cases with only peripheral VF loss (only involvement of the temporal wedge region, Bjerrum areas and/or nasal step zones in either eye) vs. controls. We implemented Bonferroni correction to account for multiple comparisons based on number of LD blocks and number of analyses. Sixty-five of the 70 SNPs analyzed fell into one of 8 LD blocks. Five SNPs were not in LD with any other SNPs (Figure 3 available at <http://aaojournal.org>). We corrected for the 8 LD blocks, 5 independent SNPs and the five analyses outcomes (by POAG overall, among women only, among men only, by paracentral VF loss, and by peripheral VF loss) to obtain a significance level of 7.7×10^{-4} (13 LD blocks \times 5 analyses=65; $0.05/65=7.7 \times 10^{-4}$)²⁸.

Results

The mean age of participants in GLAUGEN and NEIGHBOR was similar, although participants in NEIGHBOR were slightly older (Table 1). Cases in the NEIGHBOR consortium had lower IOP at study entry than cases in the GLAUGEN study (16.1 mm Hg vs. 18.0 mm Hg), higher CDR (0.76 vs. 0.67), higher pattern standard deviation on the earliest visual field (PSD) (6.67 dB vs. 5.62 dB) and more depressed mean defect on the earliest visual field (MD) (-8.38 dB vs. -5.83 dB). Females comprised 58% of GLAUGEN cases, and 52% of NEIGHBOR cases. For NEIGHBOR, 2% of cases had only paracentral initial visual field loss, while in GLAUGEN 18% of cases had only paracentral initial VF loss.

Overall, ten SNPs were significant at a Bonferroni corrected p value of 7.7×10^{-4} (top SNP rs4236601: pooled $p=2.61 \times 10^{-7}$, OR=1.26, 95% confidence interval (CI)=1.16–1.38; Table

2). Four of the ten significant SNPs are located in a regulatory region between the *CAVI* and *CAV2* genes, two are located in the 3' UTR (untranslated region) of *CAV2* and four are in the second intron of *CAVI* (Figure 2, Figure 4, available at <http://aojournal.org>). The top SNP, rs4236601 is located within the binding site for the transcription factor c-FOS, and SNPs rs10256914, rs10270569, rs3779512, and rs4736740 are in DNaseI hypersensitivity sites (regions of DNA that are gene promoters or other regulatory sites) active in human vascular endothelial cells (Figure 4, available at <http://aojournal.org>; regulatory regions determined from the ENCODE data in the UCSC Genome Browser, Available at www.genome.ucsc.edu. Accessed Sept 9, 2012).

When stratified by gender, nine of the ten SNPs showed significant associations among women (top SNP rs4236601: pooled $p=1.59\times 10^{-5}$, OR=1.30, 95% CI=1.15–1.46; Table 3) but none were significant in men (top SNP rs17588172: pooled $p=0.002$). Tests of the SNP \times gender interactions yielded no significant associations between *CAVI/CAV2* SNPs and POAG ($p=0.18$), but the slightly stronger odds ratios in women are suggestive of a differential effect.

Of the total 3108 cases, 224 had paracentral VF loss only, 993 had peripheral VF loss only, and the remaining 1891 cases were excluded from type of VF loss subanalyses because of advanced field loss making the paracentral only or peripheral only identification impossible. Analyses of POAG subgroups by type of VF loss identified five of the ten most significant *CAVI/CAV2* POAG-overall SNPs associated with paracentral VF loss only (top SNP rs17588172: pooled $p=1.07\times 10^{-4}$, OR=1.52, 95% CI=1.23–1.89; Table 4), while none of the ten were associated with POAG with peripheral VF loss only (top SNP rs4236601: pooled $p=8.03\times 10^{-4}$). Odds ratios were stronger in the analysis of POAG with paracentral VF loss only compared to the overall analysis, even though this subset contained fewer cases.

Risk allele odds ratios for the ten most significant SNPs overall were 1.15–1.26 in the overall analysis (3108 cases, 3430 controls), 1.21–1.35 in women only (1682 cases, 1937 controls) and 1.17–1.53 in cases with paracentral VF loss only (224 cases, 3430 controls), indicating the generally stronger associations in women, and in relation to POAG with paracentral VF loss only.

Discussion

In this study, we have confirmed the association between genetic variants in the *CAVI/CAV2* genomic region and POAG overall and have shown that these associations may differ by gender and for subtypes of POAG defined by pattern of visual field loss. Our group initially replicated the *CAVI/CAV2* findings in the GLAUGEN study alone,⁹ and here we have shown that meta-analyzing the results from the GLAUGEN study and with the NEIGHBOR study confirmed the association between *CAVI/CAV2* genomic region SNPs and POAG overall. For example, for the *CAVI/CAV2* SNP rs4236601, the strength of statistical association was enhanced in the combined dataset (pooled $p=2.61\times 10^{-7}$) when compared to either the GLAUGEN ($p=0.003$) or NEIGHBOR dataset ($p=1.89\times 10^{-5}$) alone. The differences in the statistical strength of the association in GLAUGEN and NEIGHBOR probably reflects the different case numbers in each cohort (Table 5, available at <http://aojournal.org>)²⁹. Our combined GLAUGEN-NEIGHBOR analysis is the largest POAG case-control sample currently available. It is possible that studies failing to replicate the POAG association with *CAVI/CAV2* SNPs were underpowered due to smaller sample size. It is also interesting that the robust association initially observed in the Icelandic population⁸ included fewer cases and hence had lower power ($n=1263$ cases; power=61%; $p=5.0\times 10^{-10}$) than the GLAUGEN-NEIGHBOR study ($n=3108$ cases; power=86%; $p=2.61\times 10^{-7}$) yet the observed associations were more significant than in the GLAUGEN-NEIGHBOR combined

dataset (Table 5, available at <http://aaojournal.org>).^{8,29} This could be due to a founder effect or a stronger allele effect in the Icelandic population

We found greater significance and stronger associations between the *CAVI/CAV2* region SNPs and POAG in women than in men, supporting the impact of estrogen on the nitric oxide pathway. Previously, our group found that *NOS3* interacts with reproductive factors such as age at menarche²³ and postmenopausal hormone use.²² Similarly, Magalhães da Silva et al. found an association between *NOS3* SNPs and POAG in women but not in men.³⁰ Since the gene product of *NOS3* (eNOS) directly interacts with caveolin 1, these genetic associations may reflect the altered protein interactions that influence the risk of POAG, especially in women.

We also found, despite a small number of cases, significant and stronger associations between the *CAVI/CAV2* region and POAG cases with only initial paracentral VF loss. Manifest visual field loss in glaucoma commonly begins peripherally and proceeds toward the center of vision; however, visual loss can commence in the paracentral region. This type of visual field deficit can substantially decrease quality of life, making reading and driving more difficult.^{31,32} Some studies, although not all,^{33–35} have suggested that paracentral visual field loss is more likely to develop in patients with IOP levels in the normal range (<22 mm Hg), indicating that risk factors other than increased IOP may contribute to this POAG subtype.^{36,37} One such factor is p53 - a functional polymorphism in *p53* was found to be associated with POAG and paracentral VF loss.³⁸ A *p53* SNP, which is thought to be functionally pro-apoptotic, may render the metabolically active maculopapillary nerve fiber bundles vulnerable to cell death resulting in paracentral VF loss seen in some POAG cases. Another major factor is systemic vascular dysregulation which has been associated with initial paracentral VF loss.²⁵ The *CAVI/CAV2-NOS3* pathway could contribute to abnormalities in systemic vascular tone and vasospastic phenomena. Recently, SNPs located in a genomic region near the *GUCY1A3/GUCY1B3* genes coding for soluble guanylyl cyclase have also been associated with paracentral VF loss in POAG.²⁶ Interestingly, the *GUCY1A3/GUCY1B3* genomic region was associated with paracentral VF primarily in women, and soluble guanylyl cyclase serves as the intracellular receptor for nitric oxide, downstream of the interaction between eNOS and caveolin 1. *CAVI* knockout mice have been studied in vascular related diseases such as atherosclerosis and pulmonary hypertension indicating a role for caveolin 1 in endothelial cell dysfunction, but the ocular phenotype of this mouse model has not been explored^{39,40}. Thus, more research into the genetic factors that determine vascular dysregulation in relation to POAG with paracentral VF loss is warranted.

The intergenic region between *CAVI/CAV2* contains several regulatory elements including H3K27Ac histone marks (indicating an active regulatory region), DNaseI hypersensitivity sites and transcription factor binding sites (Figure 2 and Figure 4, available at <http://aaojournal.org>). rs4236601 is the top SNP in our analysis and also in the Icelandic study.⁸ This SNP falls in the regulatory region 5' of *CAVI*. Several transcription factors are predicted to bind in this region including c-FOS, a transcription factor known to be active in vascular endothelial cells, especially in response to shear stress.^{41,42} Additionally, the DNaseI sites in this region are active in human vascular endothelial cell lines, and several of the significantly associated SNPs are located in these active regulatory sites. Although preliminary, these results suggest that the associated SNPs may contribute to regulation of *CAVI* and *CAV2* gene expression in human vascular endothelial cells.

There are several limitations to our study. The NEIGHBOR study contained very few cases with initial paracentral only VF defects. The majority of NEIGHBOR participants with POAG were prevalent clinic cases, which made it difficult to obtain VFs at initial disease

onset to determine the type of initial VF loss. Many of the GLAUGEN cases were incident cases identified during prospective follow-up of a population for several disease endpoints including glaucoma. Thus there was greater opportunity in GLAUGEN to access the initial VF that showed glaucomatous loss. Tests of the SNP \times gender interactions were negative because they may have been underpowered or because the true interaction involves some other gender specific trait that remains unknown. It could also be argued that our subgroup analyses may be underpowered and hence the differential significance between women only and men only and between paracentral VF loss and peripheral VF loss could represent false negatives. Despite the smaller case numbers, however, the women only and men only analyses both were adequately powered to detect a significant association (power=93%, power=84%, respectively, Table 5, available at <http://aojournal.org>)²⁹. The paracentral VF loss analysis was underpowered, with power=31%, but still found significant associations. The peripheral VF loss analysis did have adequate power (power=99%). Thus we can conclude that the differences found in the subgroup analyses are most likely not spurious.

In this study we have confirmed the association of *CAVI/CAV2* SNPs with POAG overall and have additional evidence that the relationship between *CAVI/CAV2* and POAG may be stronger in women and for POAG with initial paracentral only VF defects. Additionally, this study contributes to the emerging evidence that the nitric oxide signaling pathway plays an important role in POAG pathogenesis. Further study of the impact of *CAVI/CAV2* genetic variation on nitric oxide signaling could lead to new therapeutic targets for the treatment of POAG.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial Support: The sponsor or funding organization had no role in the design or conduct of this research.

This work was supported by the following: Genotyping services for the NEIGHBOR study were provided by the Center for Inherited Disease Research (CIDR) and were supported by the National Eye Institute through grant HG005259-01 (JL Wiggs). Additionally, CIDR is funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268200782096C. Genotyping for the GLAUGEN dataset at the Broad Institute was supported by GENEVA project grant HG004728 (LR Pasquale) and U01-HG004424 (Broad Institute). Genotype data cleaning and analysis for the GLAUGEN study was supported by U01 HG004446 (C Laurie). Collecting and processing samples for the NEIGHBOR dataset was supported by the National Eye Institute through ARRA grants 3R01EY015872-05S1 (JL Wiggs) and 3R01EY019126-02S1 (MA Hauser). Funding for the collection of cases and controls was provided by NIH grants: EY015543 (RR Allingham), EY006827 (D Gaasterland); HL73042, HL073389, EY13315 (MA Hauser); CA87969 (JH Kang), CA49449 (JH Kang), UM1 CA167552 (JH Kang), EY009149 (PR Lichter), HG004608 (C McCarty), EY008208 (FA Medeiros), EY015473 (LR Pasquale), EY012118 (M Pericak-Vance), EY015682 (A Realini), EY011671 (JE Richards), EY09580 (JE Richards), EY013178 (JS Schuman), RR015574, EY015872 (JL Wiggs), EY010886 (JL Wiggs), EY009847 (JL Wiggs), EY022766 (JL Wiggs), EY011008, EY144428 (K Zhang), EY144448 (K Zhang), EY18660 (K Zhang). JL Wiggs and LR Pasquale are supported by the Harvard Glaucoma Center for Excellence and the Margolis Fund. JL Wiggs, LR Pasquale, and JE Richards are supported by Research to Prevent Blindness. YLiu is supported by the Glaucoma Research Foundation, The Glaucoma Foundation, and American Health Assistance Foundation.

References

1. Kwon YH, Fingert JH, Kuehn MH, Alward WL. Primary open-angle glaucoma. *N Engl J Med*. 2009; 360:1113–24. [PubMed: 19279343]
2. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. *Br J Ophthalmol*. 2006; 90:262–7. [PubMed: 16488940]

3. Stone EM, Fingert JH, Alward WL, et al. Identification of a gene that causes primary open angle glaucoma. *Science*. 1997; 275:668–70. [PubMed: 9005853]
4. Rezaie T, Child A, Hitchings R, et al. Adult-onset primary open-angle glaucoma caused by mutations in optineurin. *Science*. 2002; 295:1077–9. [PubMed: 11834836]
5. Burdon KP, Macgregor S, Hewitt AW, et al. Genome-wide association study identifies susceptibility loci for open angle glaucoma at *TMCO1* and *CDKN2B-AS1*. *Nat Genet*. 2011; 43:574–8. [PubMed: 21532571]
6. Wiggs JL, Yaspan BL, Hauser MA, et al. Common variants at 9p21 and 8q22 are associated with increased susceptibility to optic nerve degeneration in glaucoma. *PLoS Genet*. 2012; 8:e1002654. serial online. Available at: <http://www.plosgenetics.org/article/info%3Adoi%2F10.1371%2Fjournal.pgen.1002654>. [PubMed: 22570617]
7. Ramdas WD, van Koolwijk LM, Cree AJ, et al. Clinical implications of old and new genes for open-angle glaucoma. *Ophthalmology*. 2011; 118:2389–97. [PubMed: 21872936]
8. Thorleifsson G, Walters GB, Hewitt AW, et al. Common variants near *CAVI* and *CAV2* are associated with primary open-angle glaucoma. *Nat Genet*. 2010; 42:906–9. [PubMed: 20835238]
9. Wiggs JL, Kang JH, Yaspan BL, et al. Common variants near *CAVI* and *CAV2* are associated with primary open-angle glaucoma in Caucasians from the USA. *Hum Mol Genet*. 2011; 20:4707–13. [PubMed: 21873608]
10. Kuehn MH, Wang K, Roos B, et al. Chromosome 7q31 POAG locus: ocular expression of caveolins and lack of association with POAG in a US cohort. *Mol Vis*. 2011; 17:430–5. serial online. Available at: <http://www.molvis.org/molvis/v17/a48/>. [PubMed: 21321670]
11. Abu-Amro KK, Kondkar AA, Mousa A, et al. Lack of association of SNP rs4236601 near *CAVI* and *CAV2* with POAG in a Saudi cohort. *Mol Vis*. 2012; 18:1960–5. serial online. Available at: <http://www.molvis.org/molvis/v18/a205/>. [PubMed: 22876122]
12. Cao D, Jiao X, Liu X, et al. *CDKN2B* polymorphism is associated with primary open-angle glaucoma (POAG) in the Afro-Caribbean population of Barbados, West Indies. *PLoS One*. 2012; 7:e39278. serial online. Available at: <http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0039278>. [PubMed: 22761751]
13. Mineo C, Shaul PW. Regulation of eNOS in caveolae. *Adv Exp Med Biol*. 2012; 729:51–62. [PubMed: 22411313]
14. Ju H, Zou R, Venema VJ, Venema RC. Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. *J Biol Chem*. 1997; 272:18522–5. [PubMed: 9228013]
15. Garcia-Cardena G, Martasek P, Masters BS, et al. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the NOS caveolin binding domain in vivo. *J Biol Chem*. 1997; 272:25437–40. [PubMed: 9325253]
16. Ellis DZ, Dismuke WM, Chokshi BM. Characterization of soluble guanylate cyclase in NO-induced increases in aqueous humor outflow facility and in the trabecular meshwork. *Invest Ophthalmol Vis Sci*. 2009; 50:1808–13. [PubMed: 19074804]
17. Mroczkowska S, Benavente-Perez A, Negi A, et al. Primary open-angle glaucoma vs normal-tension glaucoma: the vascular perspective. *JAMA Ophthalmol*. 2013; 131:36–43. [PubMed: 22964974]
18. Munaut C, Lambert V, Noel A, et al. Presence of oestrogen receptor type beta in human retina. *Br J Ophthalmol*. 2001; 85:877–82. [PubMed: 11423466]
19. Zhou X, Li F, Ge J, et al. Retinal ganglion cell protection by 17-beta-estradiol in a mouse model of inherited glaucoma. *Dev Neurobiol*. 2007; 67:603–16. [PubMed: 17443811]
20. Khorram O, Garthwaite M, Magness RR. Endometrial and myometrial expression of nitric oxide synthase isoforms in pre- and postmenopausal women. *J Clin Endocrinol Metab*. 1999; 84:2226–32. [PubMed: 10372735]
21. Hisamoto K, Bender JR. Vascular cell signaling by membrane estrogen receptors. *Steroids*. 2005; 70:382–7. [PubMed: 15862821]
22. Kang JH, Wiggs JL, Rosner BA, et al. Endothelial nitric oxide synthase gene variants and primary open-angle glaucoma: interactions with sex and postmenopausal hormone use. *Invest Ophthalmol Vis Sci*. 2010; 51:971–9. [PubMed: 19815736]

23. Kang JH, Wiggs JL, Rosner BA, et al. Endothelial nitric oxide synthase gene variants and primary open-angle glaucoma: interactions with hypertension, alcohol intake, and cigarette smoking. *Arch Ophthalmol*. 2011; 129:773–80. [PubMed: 21670344]
24. Schwartz EA, Reaven E, Topper JN, Tsao PS. Transforming growth factor-beta receptors localize to caveolae and regulate endothelial nitric oxide synthase in normal human endothelial cells. *Biochem J*. 2005; 390:199–206. [PubMed: 15819614]
25. Park SC, De Moraes CG, Teng CC, et al. Initial parafoveal versus peripheral scotomas in glaucoma: risk factors and visual field characteristics. *Ophthalmology*. 2011; 118:1782–9. [PubMed: 21665283]
26. Buys ES, Ko YC, Alt C, et al. Soluble guanylate cyclase alpha1-deficient mice: a novel murine model for primary open angle glaucoma. *PLoS One*. 2013; 8:e60156. serial online. Available at: <http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0060156>. [PubMed: 23527308]
27. Wiggs JL, Hauser MA, Abdrabou W, et al. The NEIGHBOR Consortium Primary Open-Angle Glaucoma Genome-wide Association Study: rationale, study design, and clinical variables. *J Glaucoma*. In press.
28. Tarone RE. A modified Bonferroni method for discrete data. *Biometrics*. 1990; 46:515–22. [PubMed: 2364136]
29. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. *Nat Genet*. 2006; 38:209–13. [PubMed: 16415888]
30. Magalhaes da Silva T, Rocha AV, Lacchini R, et al. Association of polymorphisms of endothelial nitric oxide synthase (eNOS) gene with the risk of primary open angle glaucoma in a Brazilian population. *Gene*. 2012; 502:142–6. [PubMed: 22561696]
31. Fujita K, Yasuda N, Oda K, Yuzawa M. Reading performance in patients with central visual field disturbance due to glaucoma [in Japanese]. *Nihon Ganka Gakkai Zasshi*. 2006; 110:914–8. [PubMed: 17134038]
32. Coeckelbergh TR, Brouwer WH, Cornelissen FW, et al. The effect of visual field defects on driving performance: a driving simulator study. *Arch Ophthalmol*. 2002; 120:1509–16. [PubMed: 12427065]
33. Motolko M, Drance SM, Douglas GR. Visual field defects in low-tension glaucoma. Comparison of defects in low-tension glaucoma and chronic open angle glaucoma *Arch Ophthalmol*. 1982; 100:1074–7.
34. King D, Drance SM, Douglas G, et al. Comparison of visual field defects in normal-tension glaucoma and high-tension glaucoma. *Am J Ophthalmol*. 1986; 101:204–7. [PubMed: 3946537]
35. Iester M, De Feo F, Douglas GR. Visual field loss morphology in high- and normal-tension glaucoma. *J Ophthalmol*. 2012; 2012:327326. serial online. Available at: <http://www.hindawi.com/journals/jop/2012/327326/>. [PubMed: 22496961]
36. Hitchings RA, Anderton SA. A comparative study of visual field defects seen in patients with low-tension glaucoma and chronic simple glaucoma. *Br J Ophthalmol*. 1983; 67:818–21. [PubMed: 6671097]
37. Caprioli J, Spaeth GL. Comparison of visual field defects in the low-tension glaucomas with those in the high-tension glaucomas. *Am J Ophthalmol*. 1984; 97:730–7. [PubMed: 6731537]
38. Wiggs JL, Hewitt AW, Fan BJ, et al. The p53 codon 72 PRO/PRO genotype may be associated with initial central visual field defects in Caucasians with primary open angle glaucoma. *PLoS One*. 2012; 7:e45613. serial online. Available at: <http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0045613>. [PubMed: 23049825]
39. Fernandez-Hernando C, Yu J, Davalos A, et al. Endothelial-specific overexpression of caveolin-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. *Am J Pathol*. 2010; 177:998–1003. [PubMed: 20581061]
40. Wunderlich C, Schmeisser A, Heerwagen C, et al. Chronic NOS inhibition prevents adverse lung remodeling and pulmonary arterial hypertension in caveolin-1 knockout mice. *Pulm Pharmacol Ther*. 2008; 21:507–15. [PubMed: 18226570]

41. Shiu YT, Li S, Yuan S, et al. Shear stress-induced c608 fos activation is mediated by Rho in a calcium-dependent manner. *Biochem Biophys Res Commun.* 2003; 303:548–55. [PubMed: 12659853]
42. Ballermann BJ, Dardik A, Eng E, Liu A. Shear stress and the endothelium. *Kidney Int Suppl.* 1998; 67:S100–8. [PubMed: 9736263]




Figure 1.

Paracentral and peripheral visual field loss definitions.

Representative grey scale and pattern deviation plot for peripheral visual field loss (A) and paracentral visual field loss (B) in two right eyes.

A. The red boxes indicate each possible peripheral visual field loss region, including inferior and superior nasal steps, temporal wedge and Bjerrum regions. A cluster of three or more points with sensitivity of -5 decibels (dB) or greater in any of these regions represents peripheral visual field loss. In this case, there is visual field loss in the inferior nasal step zone.

B. The blue boxes indicate the superior and inferior paracentral visual field loss regions. A cluster of three or more points with sensitivity of -5 dB or greater in either of these regions represents paracentral visual field loss. In this case, there is visual field loss in the inferior paracentral region. There is overlap between the paracentral zone and Bjerrum areas consisting of the second row of points. In order for the Bjerrum area to be considered to be involved there must be at least one point in the third row from the top or bottom that has a retinal sensitivity of -5 dB or more.

This figure illustrates the approach used for Humphrey visual fields. Subjects with other types of perimetric data (such as the Dicon or Octopus visual fields) were included and a similar strategy was used to grade the equivalent of the pattern deviation plot. Less than 1% of visual fields were kinetic tests and they were excluded from analyses related to pattern of field loss.




Figure 2. *CAV1/CAV2* genomic region

The *CAV1/CAV2* genomic region including all single nucleotide polymorphisms (SNPs) examined in this study and the nine significantly associated SNPs are shown using the UCSC genome browser *CAV1/CAV2* region (<http://genome.ucsc.edu>, Accessed April 2, 2013). SNPs significant overall are highlighted in black. H3K27Ac histone marks in human umbilical vascular endothelial cells (HUVEC) (typically found in genomic regions with regulatory activity) are indicated by the blue peaks. DNaseI hypersensitivity sites are represented by black rectangles.

Table 1Demographic and ocular features of GLAUGEN¹ and NEIGHBOR¹ cases and controls.

Variable ¹	GLAUGEN ¹		NEIGHBOR ¹	
	Cases	Controls	Cases	Controls
N	976	1140	2132	2290
Age (years), mean (SD)	63.6 (9.8)	65.5 (9.2)	66.6 (13.7)	68.9 (11.4)
IOP (mm Hg), mean (SD) ²	18.0 (5.6)	n/a	16.1 (6.0)	n/a
CDR, mean (SD) ²	0.67 (0.19)	n/a	0.76 (0.15)	n/a
MD, mean (SD) ^{2, 3}	-5.83 (4.94)	n/a	-8.38 (6.72)	n/a
PSD, mean (SD) ^{2, 3}	5.62 (3.05)	n/a	6.67 (3.50)	n/a
% Female	58%	60%	52%	55%
% Cases with only paracentral VF loss	18%	n/a	2%	n/a
% Cases with only peripheral VF loss	52%	n/a	23%	n/a

¹ Abbreviations: GLAUGEN=Glaucoma Genes and Environment, NEIGHBOR=National Eye Institute Glaucoma Human Genetics Collaboration, IOP=intraocular pressure, CDR=vertical cup to disc ratio, MD=mean deviation, PSD=pattern standard deviation, VF=visual field, SD=standard deviation, n/a=not available

² Means are mean of both eyes.

³ These statistics are based on Humphrey Visual Field Analyzer data available for 859 GLAUGEN participants and 1369 NEIGHBOR consortium participants. Missing data reflects the fact that some participants had visual field tests other than Humphrey tests.

⁴ These statistics are based on Humphrey Visual Field Analyzer data available for 865 GLAUGEN participants and 1371 NEIGHBOR consortium participants. Since PSD spuriously declines as MD worsens, thus subjects with MD worse than -13dB were excluded.

Table 2

Top 10 significant CAV1/CAV2 SNPs associated with POAG in meta-analysis of the combined GLAUGEN and NEIGHBOR dataset (N cases=3108, N controls=3430)^{1, 2}.

SNP	Position	Reference allele	Pooled OR (95% CI)	GLAUGEN P value	NEIGHBOR P value	Pooled P value ^{3, 4}
rs4236601	49021016	A	1.26 (1.16,1.38)	0.003	1.89×10 ⁻⁵	2.61×10 ⁻⁷
rs6969706	49020340	T	1.26 (1.15,1.38)	0.003	2.54×10 ⁻⁵	3.58×10 ⁻⁷
rs10256914	49031338	C	1.24 (1.13,1.35)	9.13×10 ⁻⁴	6.77×10 ⁻⁴	3.69×10 ⁻⁶
rs17588172	49019406	G	1.22 (1.12,1.32)	7.80×10 ⁻⁴	0.001	5.78×10 ⁻⁶
rs10270569	49033664	T	1.23 (1.12,1.35)	0.002	6. ×10 ⁻⁴	6.43×10 ⁻⁶
rs1052990	49012056	G	1.21 (1.11,1.31)	0.001	0.001	1.09×10 ⁻⁵
rs10227696	49020430	A	1.24 (1.12,1.37)	0.007	0.001	2.98×10 ⁻⁵
rs4730748	49024676	G	1.23 (1.11,1.36)	0.007	0.002	6.68×10 ⁻⁵
rs10278782	49011162	G	1.22 (1.10,1.35)	0.02	0.002	1.49×10 ⁻⁴
rs3779512	49027534	T	1.15 (1.06,1.25)	0.006	0.03	7.60×10 ⁻⁴

¹ Abbreviations: CAV1=caveolin 1; CAV2=caveolin 2; SNPs=single nucleotide polymorphisms, POAG=primary open angle glaucoma. GLAUGEN=Glaucoma Genes and Environment, NEIGHBOR=National Eye Institute Glaucoma Human Genetics Collaboration, OR=odds ratio, CI=confidence interval

² GLAUGEN N=2116 cases and controls NEIGHBOR N=4422 cases and controls

³ SNPs significant at Bonferroni corrected $p < 7.7 \times 10^{-4}$ (13 LD blocks \times 5 analyses=65, $0.05/65 = 7.7 \times 10^{-4}$) are in bold.

⁴ I^2 for heterogeneity between GLAUGEN and NEIGHBOR is > 0.33 for all SNPs.

Table 3

Top 10 significant CAV1/CAV2 SNPs overall associated with POAG in women only and men only in meta-analysis of the combined GLAUGEN and NEIGHBOR dataset¹.

SNP	Position	Reference allele	Women only (N cases=1682, N controls=1937)		Men only (N cases=1426, N controls=1493)		SNP X gender interaction P value
			Pooled OR (95% CI)	Pooled P value ^{2, 3}	Pooled OR (95% CI)	Pooled P value ^{2, 3}	
rs4236601	49021016	A	1.30 (1.15,1.46)	1.59 ×10 ⁻⁵	1.23 (1.07,1.40)	0.003	0.57
rs6969706	49020340	T	1.29 (1.15,1.46)	2.07 ×10 ⁻⁵	1.22 (1.07,1.40)	0.004	0.53
rs10256914	49031338	C	1.29 (1.14,1.45)	3.76 ×10 ⁻⁵	1.18 (1.03,1.35)	0.02	0.39
rs17588172	49019406	G	1.22 (1.09,1.36)	6.24 ×10 ⁻⁴	1.23 (1.08,1.40)	0.002	0.44
rs10270569	49033664	T	1.28 (1.14,1.45)	4.53 ×10 ⁻⁵	1.17 (1.02,1.34)	0.02	0.28
rs1052990	49012056	G	1.21 (1.08,1.35)	8.38×10 ⁻⁴	1.22 (1.07,1.38)	0.003	0.37
rs10227696	49020430	A	1.35 (1.18,1.54)	1.61 ×10 ⁻⁵	1.12 (0.96,1.31)	0.14	0.27
rs4730748	49024676	G	1.33 (1.17,1.53)	3.07 ×10 ⁻⁵	1.11 (0.95,1.29)	0.18	0.28
rs10278782	49011162	G	1.32 (1.15,1.51)	5.64 ×10 ⁻⁵	1.10 (0.94,1.28)	0.22	0.18
rs3779512	49027534	T	1.22 (1.09,1.36)	4.33 ×10 ⁻⁴	1.07 (0.95,1.22)	0.27	0.42

¹ Abbreviations: CAV1=caveolin 1; CAV2=caveolin 2; SNPs=single nucleotide polymorphisms, POAG=primary open angle glaucoma, GLAUGEN=Glaucoma Genes and Environment, NEIGHBOR=National Eye Institute Glaucoma Human Genetics Collaboration, OR=odds ratio, CI=confidence interval

² SNPs significant at Bonferroni corrected $p < 7.7 \times 10^{-4}$ (13 LD blocks \times 5 analyses=65, $0.05/65 = 7.7 \times 10^{-4}$) are in bold.

³ P for heterogeneity between GLAUGEN and NEIGHBOR is >0.20 for all SNPs.

Table 4

Top 10 significant CAV1/CAV2 SNPs overall associated with two subtypes of POAG defined by location of visual field defects (paracentral versus peripheral) in meta-analysis of the combined GLAUGEN and NEIGHBOR dataset¹.

SNP	Position	Reference allele	POAG with paracentral loss only (N cases=224, N controls=3430)		POAG with peripheral loss only (N cases=993, N controls=3430)	
			Pooled OR (95% CI)	Pooled P value ^{2,3}	Pooled OR (95% CI)	Pooled P value ^{2,3}
rs4236601	49021016	A	1.53 (1.23,1.91)	1.45 $\times 10^{-4}$	1.24 (1.09,1.41)	8.03 $\times 10^{-4}$
rs6969706	49020340	T	1.53 (1.23,1.91)	1.58 $\times 10^{-4}$	1.24 (1.09,1.41)	0.001
rs10256914	49031338	C	1.47 (1.18,1.84)	5.49 $\times 10^{-4}$	1.21 (1.06,1.38)	0.004
rs17588172	49019406	G	1.52 (1.23,1.87)	1.07 $\times 10^{-4}$	1.20 (1.07,1.36)	0.003
rs10270569	49033664	T	1.42 (1.14,1.77)	0.002	1.20 (1.05,1.37)	0.006
rs1052990	49012056	G	1.48 (1.20,1.83)	2.89 $\times 10^{-4}$	1.20 (1.06,1.35)	0.003
rs10227696	49020430	A	1.36 (1.06,1.74)	0.02	1.25 (1.08,1.44)	0.003
rs4730748	49024676	G	1.33 (1.04,1.71)	0.02	1.23 (1.06,1.42)	0.006
rs10278782	49011162	G	1.29 (1.01,1.66)	0.04	1.23 (1.06,1.42)	0.006
rs3779512	49027534	T	1.17 (0.95,1.44)	0.14	1.17 (1.03,1.31)	0.01

¹ Abbreviations: CAV1=caveolin 1; CAV2=caveolin 2; SNPs=single nucleotide polymorphisms, POAG=primary open angle glaucoma, GLAUGEN=Glaucoma Genes and Environment, NEIGHBOR=National Eye Institute Glaucoma Human Genetics Collaboration, OR=odds ratio, CI=confidence interval

² SNPs significant at Bonferroni corrected $p < 7.7 \times 10^{-4}$ (13 LD blocks \times 5 analyses=65; $0.05/65 = 7.7 \times 10^{-4}$) are in bold.

³ P for heterogeneity between GLAUGEN and NEIGHBOR is > 0.11 for all SNPs.